V. Dieras reports that there is no changes in practice after presentation of studies in triple-negative breast cancer at ASCO 2015. She elaborates the results of adjuvant phase III TITAN study that investigated a role of ixabepilone, and phase III BEACON study with etirinotecan pegol in advance setting. After that she explores the biology of disease, in particular AR and PD-L1 expression, as well as BRCA1 status that open a possibility for studying new agents.